Abstract From the moment we are born, every injury to the skin has the potential to form a scar, many of which can impair form and/or function. As such, scar management constitutes a billion-dollar industry. However, effectively promoting scarless wound healing remains an elusive goal. The complex interactions of wound healing contribute to our inability to recapitulate scarless wound repair as it occurs in nature, such as in fetal skin and the oral mucosa. However, many new advances have occurred in recent years, some of which have translated scientific findings from bench to bedside. In vivo lineage tracing has helped establish a variety of novel cellular culprits that may act as key drivers of the fibrotic response. These newly characterized cell populations present further targets for therapeutic intervention, some of which have previously demonstrated promising results in animal models. Here, we discuss several recent studies that identify exciting approaches for diminishing scar formation. Particular attention will also be paid to the canonical Wnt/β-catenin signaling pathway, which plays an important role in both embryogenesis and tissue repair. New insights into the differential effects of Wnt signaling on heterogeneous fibroblast and keratinocyte populations within the skin further demonstrate methods by which wound healing can be re-directed to a more fetal scarless phenotype.
Introduction
Human skin has evolved the remarkable ability to repair itself after injury. An unavoidable consequence of the skin's rapid wound healing process is the formation of fibrotic scar tissue. Whereas the presence of a scar for some is merely a cosmetic concern, scars of the face and large burn scars can be severely debilitating. Children are particularly prone to the effects of scarring and suffer from long-term physical (Sheridan et al. 2000) and psychological (Robert et al. 1999 ) harm after developing large scars from surgery or burns. In the United States, $7.5 billion is spent annually on burn care (Finkelstein et al. 2006) , and much of the effort spent treating burn patients is related to the burn scar. With regard to nonburn scars, 80 million surgical incisions (CDC 2010; Cullen et al. 2009 ) and 12 million traumatic lacerations (Singer et al. 1997) occur in the United States annually, resulting in a potential $12 billion market for the treatment of the resulting scars (Sen et al. 2009 ).
The ability to encourage cutaneous injuries to heal without fibrosis would revolutionize the care of lacerations, incisions, and burns and would alleviate an enormous amount of suffering. A major advance in the science of scarring took place when we recognized that the skin of the fetus in mammals heals without scars early in gestation. The oral mucosa demonstrates a similar privileged scarless phenotype following wounding. Unfortunately, wound therapies that result in tissue regeneration in place of physiological reparative healing with scar formation have yet to be realized clinically.
The more recent appreciation of the functional and topographical heterogeneity of cells collectively known as fibroblasts has advanced our ability to more specifically target cells involved in wound healing, with fewer systemic consequences. Although relevant therapeutic interventions are fairly novel, the generalizability of characterizing and targeting specific subsets of cell populations is likely to open many new doors in treating fibrotic disease. In preparation for a proliferation of such studies, we present an overview of our current ability to modulate the wound healing process in favor of a regenerative scarless phenotype. Special attention will be paid to canonical Wnt/β-catenin signaling, long understood to influence both embryological development and wound healing, as many recent studies have focused on its influence over specific subsets of cells within the dermis and epidermis.
Heterogeneity of skin cell populations
Recent advances in stem cell biology have added insight into our understanding of wound healing. The discovery of longlived epithelial stem cells (ESCs) in the hair follicle bulge region led to the hypothesis that development and repair were dependent on these cells. However, fate-mapping experiments revealed that ESCs in the bulge region do not normally contribute to the epidermis but respond to wounding by generating short-lived transient amplifying cells (TACs) responsible for acute wound repair (Ito et al. 2005) . Recently, the cellular heterogeneity of the interfollicular epidermis (IFE) has been examined by using clonal fate analysis and has been shown to consist of slow-cycling stem cells and committed progenitor cells. After wounding, only stem cells contribute substantially to the repair and long-term regeneration of the tissue (Mascre et al. 2012) .
In the dermis, a population of mesenchymal cells, known as dermal papilla (DP) cells, are thought to regulate hair follicle growth and development and to serve as a reservoir of multipotent stem cells (Driskell et al. 2011) . Another population of cells, known as skin-derived precursors (SKPs), derive from Sox2 + follicle-associated dermal precursors and have been shown to contribute to dermal maintenance, wound healing, and hair follicle morphogenesis. SKPs self-renew and maintain their pluripotency, exhibiting functional properties of an adult dermal stem cell (Biernaskie et al. 2009 ). Recently, Driskell et al. (2013) have determined that dermal fibroblasts arise from two distinct lineages that form the upper and lower dermis. Whereas the upper papillary dermis contributes to re-epithelization and hair follicle formation, the lower dermis comprises the reticular fibroblasts that synthesize the bulk of the fibrillar extracellular matrix (ECM) and mediate dermal repair after wounding. These fibroblasts are the first to infiltrate the wound bed during healing and demonstrate a myofibroblastic phenotype with α-smooth muscle actin (α-SMA) expression (Driskell et al. 2013) .
The appreciation of the functional heterogeneity of dermal fibroblasts has led to advances in our understanding of their responses to signaling pathways during the wound healing process. The distinct lineages of dermal fibroblasts demonstrate differential responses to epidermal Wnt/β-catenin paracrine signaling. Specifically, epidermal Hedgehog (Hh) promotes papillary fibroblast proliferation, whereas transforming growth factor-β (TGF-β) mediates ECM remodeling in the reticular dermis. Pharmacological inhibition of either TGF-β or Hh has been shown specifically to target these fibroblast lineages (Lichtenberger et al. 2016) . Although the authors did not directly study wound healing and scar formation, their findings did corroborate the findings of Rinkevich et al. (2015) , as they relate to a fibroblast lineage originating from Engrailed-1 (En1)-expressing progenitors. Both the reticular fibroblasts of Lichtenberger, which co-express Sca1 and CD26, and the CD26 + fibroblasts derived from En1 + embryonic cells, were found to comprise 70-80 % of all dermal fibroblasts, cells that are responsible for the bulk of connective tissue deposition in the dorsal dermis leading to scar formation (Lichtenberger et al. 2016; Rinkevich et al. 2015) . Overall, these studies have improved our understanding of stem cell biology and wound healing, giving hope for improving aberrant wound repair (Fig. 1 ).
Scarless wound healing as it occurs in nature
Fetal scarless wound healing Interestingly, wounds in the early, but not late, mammalian gestational period heal without the formation of scars in a process resembling regeneration (Gurtner et al. 2008) . Although the exact mechanism is as-yet unknown, many characteristics of the fetal skin differentiate it from adult skin, both at the cellular level and at the tissue level (Fig. 2) . One notable feature is the decreased tensile strength in early fetal skin. Based on this observation, a study by Wong et al. (2012) has elucidated focal adhesion kinase (FAK) as the pathway that ties mechanotransduction with fibrosis. FAK, through extracellular-related kinase (ERK), triggers the secretion of monocyte chemoattractant protein-1 (MCP-1), which has been associated with a number of human fibrotic disorders (Wynn 2008) . By knocking out or inhibiting various components of the inflammatory FAK-ERK-MCP-1 pathway, scar formation is attenuated (Wong et al. 2012) . This work has translated to the development of a stress-shielding device that has been shown in two randomized controlled clinical trials to reduce scar formation (Lim et al. 2014; Longaker et al. 2014) . Early gestational cells may also modify their embryonic niche in a way that promotes regenerative healing, whereas the cells of late gestation may be restricted to reparative healing. As an example, human keratinocytes from mid-gestation have the ability to modulate fibroblast gene expression, causing increased proliferation and migration relative to co-culture with late-gestation fibroblasts . Moreover, proteome analysis of cultured fibroblasts has revealed different patterns of protein expression in a comparison of adult and fetal fibroblasts, further supporting scar formation during wound healing as a cell-intrinsic property (Ho et al. 2014 ).
Oral mucosa
In adult mammals, healing of the oral mucosa provides the closest example of regenerative healing as it demonstrates very minimal scarring. Inflammation at the wound bed is known to contribute to the formation of a scar. Both oral mucosa and fetal skin may be considered as Bprotected environments^for wound healing. Human fetal skin was observed to heal without scar when transplanted subcutaneously into immunodeficient nude mice, whereas cutaneous transplantation of age-matched fetal skin resulted in scar formation (Lorenz et al. 1992) . Similarly, in the oral cavity, salivary mucins form hydrophilic viscoelastic gels that, in turn, act as barriers protecting the underlying mucosa from mechanical damage and direct interaction with pathogens and other harmful substances (Amerongen and Veerman 2002) . However, the role of this Bprotected environment^has been determined to be necessary but insufficient to achieve scarless wound healing, given that adult skin transplanted to the fetus heals with a scar following incisional wounding (Longaker et al. 1994) .
Analysis of healthy human oral mucosa revealed significantly lower numbers of neutrophils and macrophages, compared with healthy skin (Glim et al. 2015) . However, the authors were unable to study these differences in acute wounds. The attenuated inflammatory environment of the oral mucosa likens it to the fetal wound healing environment and may partially explain the similarities in reduced scar formation. ECM composition prior to wounding has also been hypothesized as a contributor to privileged scarless healing. Relative to skin, the oral mucosa exhibits increased fibronectin, its splice variant ED-A, and chondroitin sulfate (Glim et al. 2014) . Pro-fibrotic myofibroblast α-SMA expression relies on cell surface ED-A fibronectin interaction in addition to TGF-β1 (Tomasek et al. 2002) . Conversely, the presence of elastin was more pronounced in the skin. Additionally, the rate of proliferation was higher in oral keratinocytes, with keratinocytes located in the dermis demonstrating increased differentiation (Glim et al. 2014) . The unique characteristics of the oral mucosa relative to the cutaneous skin contribute to its ability to heal with minimal scarring. However, significant advances are required to establish this privileged healing in cutaneous wounds.
Recent advances in scarless wound healing research Administration of therapeutics with known anti-inflammatory activity
Fetal scarless wound healing is associated with significantly reduced inflammation, whereas pathological scarring often involves an unregulated inflammatory response (Larson et al. 2010) . Therefore, significant effort has been devoted to modulating the inflammatory processes that may negatively impact wound healing. Utilization of physiological antiinflammatory molecules offers the potential to direct wound healing down regenerative pathways. For example, systemic administration of the neuropeptide α-melanocyte-stimulating hormone (α-MSH) leads to a more regenerative healing process characterized by less macroscopic scar formation and the organization of collagen fibers more closely mimics that of unwounded skin (de Souza et al. 2015) . Although this effect requires administration of α-MSH prior to wounding, the prophylactic administration of anti-fibrotic agents is not without clinical utility, particularly in cases such as scar revision surgery.
Fibroblast growth factor 9 (Fgf9) also provides a means for modulating the inflammatory environment, for example, by promoting monocyte to M2 macrophage differentiation in cardiac ischemic injury (Singla et al. 2015) . Importantly, in cutaneous injury, Fgf9 from dermal γδ T cells has been shown by Gay et al. (2013) to facilitate follicle neogenesis. In humans, wound healing with scar formation occurs without the regeneration of hair follicles. Given that Fgf9 overexpression potentiates increased follicle neogenesis in mice, these findings might translate to therapies promoting regenerative healing (Gay et al. 2013) .
In a study by Morris et al. (2014) , the authors aimed to improve their understanding of the influence of wound size and inflammation on fetal ability to undergo regenerative healing rather than scar formation. Larger (8-mm) wounds created in fetal lambs were found to heal with scar formation, whereas 2-mm wounds healed without scars. These findings also correlated with a difference in gene expression profiles and increased inflammation in large fetal wounds. Administration of lentiviral interleukin-10 (IL-10) resulted in the restoration of normal skin architecture and the attenuation of pro-inflammatory gene expression (Morris et al. 2014) . However, the use of viral vectors is greatly limited in clinical practice, because of the risks of oncogenesis. Nonetheless, low concentrations of recombinant human IL-10 injected intradermally in humans prior to incision showed improved macroscopic scar appearance at 12 months (Kieran et al. 2013) .
Findings of upregulated stromal-cell-derived factor 1 (SDF-1)/C-X-C chemokine receptor type 4 (CXCR-4) after burn injury and subsequent hypertrophic scar formation have also led to novel therapeutic targets, as CXCR-4 antagonism inhibits inflammatory cell recruitment and fibroblast activation. In this case, Ding et al. (2014) transplanted splitthickness human skin grafts into full-thickness wounds in nude mice. Serial injection of the CXCR-4 antagonist CTCE-9908 resulted in grafts that remained flat, with only limited contraction, contrary to findings in controls demonstrating more hypertrophic scars. Results of associated gene and protein expression studies, coupled with an analysis of tissue architecture and cell recruitment, collectively suggest that CXCR-4 antagonism exhibits a potent anti-fibrotic and pro-regenerative phenotype (Ding et al. 2014) . Limiting the fibrotic response following skin grafting has the potential to reduce functional deficits attributable to contractures, particularly when grafts are placed over mobile joints. Furthermore, such therapies might preclude the need to harvest fullthickness skin grafts, which demonstrate less contraction relative to split-thickness skin grafts.
Cellular targets for scarless wound healing
Advances in developmental biology, by lineage tracing and transplantation assays, have allowed researchers to identify populations of cells contributing to scar formation. Dulauroy et al. (2012) utilized transient expression of a disintegrin and metalloprotease 12 (ADAM12) to distinguish a proinflammatory subset of perivascular cells that are activated upon acute injury in muscle and dermis. Ablating these cells or knocking down ADAM12 was sufficient to decrease fibrosis and scarring (Dulauroy et al. 2012) . Recent studies by Rinkevich et al. (2015) have further elucidated the heterogenic nature of dermal fibroblast populations. Of particular interest, fibroblasts originating from En1-lineages have been identified as the main culprits in the cutaneous scarring that occurs beyond early gestation. These cells act as the major contributor of connective tissue in scar formation. Concomitant expression of the CD26 (also known as dipeptidyl peptidase-4, DPP4) surface marker allows the selective abrogation of the En1-fibroblast lineage with diprotin A. Treatment with this small molecule reduces cutaneous scarring secondary to fullthickness excisional wounding without compromising the integrity of the healed tissue (Rinkevich et al. 2015) . In vivo experiments have demonstrated the ability of DPP4 inhibitors to curb the fibrogenic phenotypes of keloid-derived fibroblasts and normal fibroblasts. The underlying mechanisms associated with the observed decrease in collagen production and TGF-β1 expression involve the pro-fibrotic pp38 and pERK1/2 pathways (Thielitz et al. 2008) .
Myofibroblasts are key players in the normal wound healing response, contributing to wound contraction and ECM production (Gurtner et al. 2008) . Cells demonstrating persistent myofibroblast-like phenotypes are key contributors to pathological fibrosis, making them ideal targets for reducing scar formation, given their association with excess ECM deposition and disinhibited contraction (Powell et al. 1999) . This is in contrast to the maturation phase of normal wound healing, during which these cells largely undergo apoptosis (Desmouliere et al. 1995) . Reversal of the myofibroblast phenotype might also contribute to decreased numbers of these cells (Desai et al. 2014; Maltseva et al. 2001) . Similarly to fibroblasts, myofibroblasts (or myofibroblast-like cells) have also been determined to be a functionally heterogeneous cell population, with numerous potential precursors, including fibroblasts, mesenchymal stem cells (MSCs), smooth muscle cells, endothelial cells, and fibrocytes (Hinz et al. 2007 ). Adipocytes have also been found to appear simultaneously during wound healing. Although we remain uncertain as to whether fibroblasts and adipocytes share a common progenitor, Schmidt and Horsley (2013) have demonstrated that dermal adipocytes, via intercellular communication, are necessary for fibroblast recruitment in wound healing. Thus, experimental interventions have been targeted at a variety of cell populations, both directly and indirectly responsible for scar formation.
Studies conducted by Desai et al. (2014) have demonstrated both the ability to differentiate myofibroblast precursors (adipose-derived mesenchymal stem cells, ASCs) directly away from a myofibroblastic phenotype and to reverse differentiated cells towards a more fibroblast-like phenotype. Specifically, they have shown that myofibroblastic cells treated with basic fibroblast growth factor (bFGF) exhibit diminished expression of α-SMA, collagen I, and fibronectin, and a loss of focal adhesions and stress fibers. These cells were, moreover, more migratory, being associated with tenascin-C and vimentin upregulation, in agreement with a more fibroblast-like phenotype. Their findings suggest that the myofibroblast differentiation process is not terminal, elucidating bFGF as a phenotypic reversing agent (Desai et al. 2014) .
Extracorporeal shockwaves (ESW), more commonly used in urological or orthopedic interventions, may also have a role in reducing scar formation. ESW treatment caused myofibroblast precursors to differentiate into more fibroblast-like cells with lower contractility and higher migration potential, simultaneously reducing α-SMA and type I collagen expression (Rinella et al. 2016 ).
Stem cells and scarless wound healing
Stem-cell-based wound therapies are generally directed at treating recalcitrant wounds, whereas their potential for scarless wound healing has been less well established in vivo. Stem cells have certainly demonstrated an ability to modulate the wound environment to improve healing, in part by reducing inflammation (Corcione et al. 2006; Di Nicola et al. 2002; Loots et al. 1998 ). However, whether this translates to significant decreases in scarring is unclear, as a result of sometimes conflicting findings (Doi et al. 2016; Sabapathy et al. 2014) . Furthermore, practical barriers associated with stem-cellbased therapies might restrict their utility in pursuit of scarless wound healing (Nuschke 2014) . Despite the potential limitations of direct stem-cell-based scarless wound therapies, one recent study by Li et al. (2015) has demonstrated the potential benefits of conditioned media from umbilical cord (UC)-MSC cultures. Dermal fibroblasts under the paracrine influence of these cells exhibit characteristics reminiscent of fetal fibroblasts, such as low capacity to form myofibroblasts, a decreased TGF-β1/TGF-β3 ratio, and increased expression of enzymes involved in ECM remodeling (matrix metalloproteinases, MMPs). Wounds treated with UC-MSC-conditioned media also healed faster with decreased collagen accumulation (Li et al. 2015) . Additionally, in vitro studies have shown that human amniotic-fluid-derived MSC-conditioned media has the potential to inhibit the pro-fibrotic actions of TGF-β1 and even reverse the myofibroblast phenotype to a fibroblast-like state. Conditioned media from ASCs produced similar results, but to a lesser extent (Mia and Bank 2015) . Taken together, these findings suggest that stem cells are able to promote a scarless phenotype without the requirement for direct inoculation to the wound bed, thus drastically reducing the risk of resultant oncogenesis (Fig. 3) .
Wnt and regeneration
Analysis of gene expression in fetal mouse keratinocytes and fibroblasts at embryonic day (E)16 and E18 time points, straddling the transition from scarless to scarforming repair has revealed numerous differentially regulated pathways, such as canonical Wnt/β-catenin signaling; many others have yet to be examined under the lens of wound healing (Hu et al. 2014) . These pathways create numerous novel targets to modulate the wound healing process toward a more scarless phenotype (Fig. 4) .
Wnt signaling is a key component of embryological development but is also involved in all phases of the wound healing response. Of the various subsets of the Wnt signaling pathways, the canonical Wnt pathway is most relevant to tissue regeneration and repair and will be the focus of this section. Particular emphasis will be placed on the influence of Wnt signaling in wound healing as it pertains to scar formation (for a more in-depth review of the role of Wnt signaling in tissue renewal and regeneration, the reader is directed to the following review article: Clevers et al. 2014) . In this pathway, Wnt-ligand binding at the cell surface leads to cytoplasmic β-catenin accumulation, which would otherwise be degraded by the APC/Axin/GSK3 complex. β-catenin subsequently translocates to the nucleus to exert its effects as a transcriptional co-activator (Houschyar et al. 2015) .
Many studies have elucidated a link between TGF-β and the canonical Wnt/β-catenin pathway in fibrosis. For example, analysis of pathological scars (hypertrophic scars and keloids) has uncovered upregulated Wnt signaling secondary to TGF-β (Sato 2006) . Even in normal wound healing with scar formation, β-catenin levels have been shown to double during the proliferative phase (Cheon et al. 2002) . Another study has found that human keloids display Wnt-3a overexpression, inducing fibroblasts of endothelial origin to transition to mesenchymal cells, which in turn lead to collagen accumulation (W.J. . Though Wnt-3a is known to downregulate CD31 expression, whether these cells are directly related to the aforementioned ADAM12 + lineage, which are CD31 prompted the development of other novel therapies that take advantage of the paracrine mechanisms of action of these cells. Application of conditioned media from umbilical cord blood-derived MSC (UCB-MSC) culture is one such example (Doi et al. 2016) remains unclear (Dulauroy et al. 2012) . Future studies might translate our understanding of these endothelial or perivascular progenitors in order to eliminate fibrosis in wound healing. Whereas TGF-β signaling is central to the pro-fibrotic fibroblast phenotype, several studies have shown that the Wnt pathway is an important mediator. For example, Cheon et al. (2006) demonstrated that TGF-β1 is unable to promote hyperplastic wounds in transgenic mice lacking β-catenin. Akmetshina et al. (2012) found that TGF-β downregulates the Dickkopf-1 (Dkk-1) Wnt-antagonist, thereby upregulating the canonical Wnt signaling pathway. This claim has further been substantiated by the enhanced Wnt and decreased Dkk-1 expression in fibrotic human tissue samples. In a transgenic mouse line overespressing endogenous Dkk-1, this translates to prevention of bleomycin-induced fibrosis (Akhmetshina et al. 2012) . However, topical application of Dkk-1 in a fullthickness excisional model inhibits wound healing . Therefore, the harnessing of Dkk-1 for therapeutic intervention will require further insight into its mechanism of action, particularly as it relates to fibrotic etiology and means of administration.
Modulation of the Wnt/β-catenin pathway is not restricted to the use of endogenous mediators. Bastakoty et al. (2015) have demonstrated the potential therapeutic nature of small molecules to promote a regenerative wound healing phenotype. Topical application of Wnt pathway inhibitors (XAV-939, a tankyrase inhibitor, and pyrvinium, a casein kinase activator) leads to the formation of rete pegs and dermal papillae following wound closure. These structures are found in intact skin rather than a mature scar. Scar formation is also inhibited, as demonstrated by fewer myofibroblasts expressing α-SMA and reduced type I collagen synthesis. Wnt activation with lithium chloride (LiCl) in turn reduces regenerative repair (Bastakoty et al. 2015) . However, in a full thickness excisional wound model in rats, topical LiCl application demonstrated the reduction in gross scar appearance without impacting time to wound closure . As is the case with therapeutic Dkk-1 administration, more studies are needed to produce the desired regenerative healing phenotype in vivo.
A recent study by S.H. demonstrates the balance that must be struck in regulating pathways of wound healing, such as Wnt, in the pursuit of improved wound healing. Here, the authors have demonstrated that CXXC5, a zinc finger family protein, inhibits β-catenin and blocks wound healing in part by decreasing contraction and collagen production in dermal fibroblasts-myofibroblast-like features of dermal fibroblasts. The authors have subsequently developed synthetic peptides to block interactions between CXXC5 and Dishevelled (Dvl), a mediator of Wnt signaling, which together lead to β-catenin degradation. Whereas the topical treatment of cutaneous wounds in mice results in faster healing, which can be further accelerated with positive Wnt regulators, this therapy might result in more scar formation. However, the authors have not quantified the final scar size across treatment and control groups (S.H. . Not only do cells exhibit different genetic expression profiles as they transition into the adult scar-forming phenotype, the developmental stage and tissue of origin also dramatically impact the way that fibroblasts respond to Wnt signaling (Lam and Gottardi 2011) . For example, Carre et al. (2010) have elucidated differences between mouse embryonic (E16.5) and postnatal (P1) fibroblasts following stimulation with Wnt-3a. Wnt-3a increased postnatal, but not fetal, fibroblast proliferation, with concomitant collagen type I synthesis. Furthermore, recombinant Wnt-3a produced similar findings to the administration of pro-fibrotic TGF-β1 and also shifted the postnatal fibroblast expression of TGF-β isoforms toward that of scarring wounds, with increased TGF-β1 and decreased TGF-β3. Finally, based on gene expression analyses, endogenous Wnt signaling has been found to be elevated, but to a substantially lesser degree, in fetal cutaneous wound repair compared with that in adult skin (Carre et al. 2010) .
Despite these findings, by inducing sustained epidermal β-catenin signaling, Collins et al. (2011) have observed increased fibroblast proliferation and enhanced remodeling of the dermal ECM at levels akin to neonatal dermis. The connective tissue composition also more closely resembles developing skin (Collins et al. 2011) . Furthermore, the activation of epidermal Wnt/β-catenin signaling can cause expansion of the upper dermal fibroblast lineage, which in turn allows hair follicle growth not traditionally observed in physiological wound healing (Driskell et al. 2013; Gurtner et al. 2008) . This observation has led some to conclude that the upper dermal fibroblasts could be utilized as a means for resolving scar formation and promoting scarless wound healing, given their more abated fibrillary collagen production relative to the lower dermis lineage (Driskell and Watt 2015) .
Many Wnt studies in skin have focused on its role in hair follicle neogenesis and its involvement in cutaneous homeostasis and regeneration. While researchers such as Bastakoty et al. (2015) specifically targeted the dermis with topical application of Wnt modulators/inhibitors, many other studies into the skin regenerative phenotype have focused on follicular neogenesis, relying on epithelial or follicle-specific paracrine Wnt signaling (Bastakoty et al. 2015; Ito et al. 2007) . Following full-thickness wound epithelialization, Ito et al. (2007) noted that formation of de novo hair follicles both requires Wnt signaling and is promoted by Wnt overexpression. Given that mammalian hair follicles are believed to form only during embryonic development, the authors postulate that wounding might induce an embryonic phenotype in the skin, which in turn can be regulated by Wnt proteins (Ito et al. 2007 ). Specific models used to study the impact of Wnt in scar formation might differ in part because of the transient mode of action and the different means by which this pathway is manipulated experimentally. For example, longterm Wnt activation limits the efficacy of small molecule Wnt inhibitors (de la Roche et al. 2014) . The differential outcomes of Wnt stimulation based on target tissues, partly related to the mode of Wnt pathway modulation, is likely to account for some of the aforementioned discrepancies relating to the upregulation of the canonical pathway either promoting or inhibiting scarless wound healing.
MicroRNA
MicroRNA (miRNA) gene therapies are another more recent avenue for potential therapeutic interventions. These molecules exert an inhibitory role on mRNA transcription within eukaryotic cells, effectively silencing genes at a posttranscriptional level (Sen and Ghatak 2015) . Comparison of genome-wide miRNA expression between mid-gestational (E16) and late-gestational (E19) mouse skin discovered global repression of these molecules at the earlier time point, a period during which the skin is known to heal without scar formation (Cheng et al. 2010) . In human fetal keratinocytes, Zhao et al. (2015) established the miR-34 family as potential candidates for scarless wound healing. Expression of these miRNAs was significantly lower in late-as compared with mid-gestational keratinocytes. This family might also heavily suppress genes involved throughout the TGF-β pathway . Numerous tools have been developed to modulate cell and tissue miRNA levels, several of which have been directed toward regenerative wound healing. For example, miR-145 has been found at three times its normal levels in hypertrophic scars and pro-fibrotic TGF-β1-induced myofibroblasts. Using a commercial inhibitor of miR-145, Gras et al. (2015) were able to show a significant decrease in type I collagen expression, TGF-β1 secretion, and contractility in skin myofibroblasts. Additionally, miRNAs can be combined with biomimetic scaffolds to enhance wound healing, furthering their clinical potential (Monaghan et al. 2014) . Future in vivo studies will hopefully enumerate the clinical potential for other miRNA-based therapies.
Concluding remarks
Aberrant wound healing, scarring, and fibrosis result in a tremendous burden on public health. Thankfully, in this regard, recent advances in stem cell and developmental biology have elucidated novel pathways and cell types involved in scarring and fibrosis. However, to accelerate generalizability and translation, future studies aimed at assessing therapeutic potential for scarless wound healing would benefit from a more standardized model. Commonly, decreased scarring is interpreted from histological data that show reduced collagen staining. Whereas collagen accumulation is a fundamental component of scar formation, clinically speaking, macroscopic cutaneous scarring most negatively impacts form and function following wound healing. Therefore, studies would benefit from a macroscopic assessment of scar size in wound healing models. Additionally, the translation of research findings may be aided through the utilization of a humanized wound model, relying either on porcine tissue or splinted murine skin, as looseskinned animals heal primarily by contraction, whereas humans heal by granulation tissue formation (Galiano et al. 2004) . Increased standardization and rigor in defining the factors that truly promote scarless wound healing in vivo will also improve generalizability and translatability of findings.
Although stem-cell-based therapies may provide a more complex mélange of factors to promote scarless wound healing, many barriers to their utility still exist. By definition, stem cells are multipotent or pluripotent and thus carry a potential risk of tumor formation. These cells also exhibit difficulties in survival and engraftment following administration. However, the latter might be less of an issue given their largely paracrine mechanisms of action and the therapeutic benefits of stem-cell-conditioned media (Cerqueira et al. 2015) . Conversely, molecular therapies offer increased specificity in their targets, allowing for more predictable effects. However, individual agents may be inadequate to successfully augment the complex wound healing process to the more privileged regenerative phenotype. Combinations of endogenous and exogenous wound healing modulators are likely to prove to be the most practical means of successfully and reproducibly achieving scarless wound repair in patients. As our comprehension of regenerative over reparative healing increases, the translation of an improved understanding of scarring from fundamental science should result in novel clinical therapeutics.
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